BBIO vs. SMMT: BridgeBio Pharma vs. Summit Therapeutics Stock Comparison
How do BridgeBio Pharma (BBIO) and Summit Therapeutics (SMMT) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
BridgeBio Pharma (BBIO) and Summit Therapeutics (SMMT) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.
| Profile Item | BBIO | SMMT |
|---|---|---|
| Name | BridgeBio Pharma Inc. | Summit Therapeutics Inc. |
| Country/Region | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Biotechnology |
| GICS Sub-Industry | Biotechnology | Biotechnology |
| Market Capitalization | 14.47 billion USD | 13.06 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | Nasdaq |
| Listing Date | June 27, 2019 | March 5, 2015 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| Total Return (1Y) | 22.70% | -2.48% |
| Total Return (3Y, Annualized) | 40.97% | 116.18% |
| Total Return (5Y, Annualized) | 8.25% | 26.89% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
Summit Therapeutics (SMMT) reports a negative beta of -1.51, suggesting inverse market sensitivity over the measurement window. That is uncommon for ordinary equities and can reflect commodity-linked or hedge-like exposure, but it can also come from statistical noise. BridgeBio Pharma (BBIO) has a non-negative beta of 0.93.
| Metric | BBIO | SMMT |
|---|---|---|
| Volatility (1Y, Annualized) | 44.39% | 75.06% |
| Beta (5Y) | 0.93 | -1.51 |
| Max Drawdown (5Y) | -89.79% | -87.64% |
| Avg. Volume (3M) | 2.68M | 6.19M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| Sharpe Ratio (1Y) | 0.41 | -0.09 |
| Sortino Ratio (1Y) | 0.63 | -0.13 |
Profitability
ROE (TTM)
BridgeBio Pharma (BBIO) has no ROE value reported for this period; Summit Therapeutics (SMMT) reports a negative figure of -220.01%, which needs context because negative ROE can reflect losses or negative shareholders’ equity.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- BBIO
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
-220.01%
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- SMMT
- -220.01%
Net Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-59.84%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
- BBIO
- -59.84%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 18.05%
- Q3
- 4.78%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile Summit Therapeutics (SMMT) reports 0.00%, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-3.30%
- Max
- 83.12%
- Q3
- 14.77%
- Median
- 0.00%
- BBIO
- -3.30%
- Q1
- -78.82%
- Min
- -207.40%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- Max
- 83.12%
- Q3
- 14.77%
- SMMT
- 0.00%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| ROE (TTM) | -- | -220.01% |
| ROA (TTM) | -13.97% | -111.99% |
| Net Margin (TTM) | -59.84% | 0.00% |
| Operating Margin (TTM) | -3.30% | 0.00% |
| Gross Margin (TTM) | 94.34% | 0.00% |
Growth
Revenue Growth
Only one side can be read here: BridgeBio Pharma (BBIO) reports revenue growth of 126.26%, ranked against its industry; Summit Therapeutics (SMMT) has no revenue growth figure this period.
EPS Growth
Neither BridgeBio Pharma (BBIO) nor Summit Therapeutics (SMMT) reports a EPS growth value for this period, so a direct comparison isn't possible.
Growth Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| Revenue Growth (YoY) | 126.26% | -- |
| Revenue Growth (3Y CAGR) | 86.30% | -- |
| EPS Growth (YoY) | -- | -- |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Summit Therapeutics (SMMT) at 5.99 keeps current ratio within its industry’s typical mid-range, while BridgeBio Pharma (BBIO) at 2.09 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for BBIO.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.09
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- BBIO
- 2.09
- Min
- 0.10
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.99
- Max
- 25.13
- Q3
- 12.13
- SMMT
- 5.99
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
Debt / Equity (MRQ)
Only one side’s leverage can be read here: Summit Therapeutics (SMMT) carries debt-to-equity ratio of 0.04 against its industry range, while BridgeBio Pharma (BBIO) reports no figure this period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
- BBIO
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.04
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- SMMT
- 0.04
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| Current Ratio (MRQ) | 2.09 | 5.99 |
| Debt / Equity (MRQ) | -- | 0.04 |
| Net Debt / EBITDA | -- | -- |
Dividends
Dividend Yield (TTM)
Neither BridgeBio Pharma (BBIO) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Summit Therapeutics (SMMT) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- BBIO
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- SMMT
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Neither BridgeBio Pharma (BBIO) nor Summit Therapeutics (SMMT) reports a P/E ratio value for this period, so a direct comparison isn’t possible.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- BBIO
- --
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 85.34
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
- SMMT
- --
P/S Ratio (TTM)
A sales-based read is only available for BridgeBio Pharma (BBIO), whose P/S ratio of 15.31 ranks against industry peers; Summit Therapeutics (SMMT) reports no figure this period.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
15.31
- Max
- 58.18
- Q3
- 25.77
- BBIO
- 15.31
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
- SMMT
- --
P/B Ratio (MRQ)
BridgeBio Pharma (BBIO) reports a negative P/B ratio of -5.59, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Summit Therapeutics (SMMT) reports 23.13, ranking against industry peers normally.
BBIO
Pharmaceuticals, Biotechnology & Life Sciences industry group
-5.59
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- BBIO
- -5.59
- Min
- -5.59
SMMT
Pharmaceuticals, Biotechnology & Life Sciences industry group
23.13
- SMMT
- 23.13
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | BBIO | SMMT |
|---|---|---|
| P/E Ratio (TTM) | -- | -- |
| P/S Ratio (TTM) | 15.31 | -- |
| P/B Ratio (MRQ) | -5.59 | 23.13 |
| Free Cash Flow Yield (TTM) | -1.98% | -1.64% |